drugset / Trial / NCT00005986

Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia

NCT00005986

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of chemotherapy and filgrastim followed by peripheral stem cell transplantation in treating patients who have chronic myelogenous leukemia.

Timeline

Start
2000-08
Primary completion
2004-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Busulfan Small molecule Oral
Subject Cyclophosphamide Other / unclassified Intravenous
Subject filgrastim Protein / enzyme biologic Subcutaneous
Background interferon alfa-2b Protein / enzyme biologic Subcutaneous

Indications